Replies to post #108755 on Biotech Values

[mcbio]

The US basic Zyvox patent, expires in 2015 (including the 6-month
pediatric exclusivity period), and another patent that expires in 2021. So, Zyvox patent would not expire until at least 2014 but Teva might win the case in court before.

Thanks genisi, very helpful. I'm assuming the chances are close to nil that the other patent expiring in 2021 can keep a generic Zyvox off the market until then. Is that an accurate assumption? I am hoping that TSRX can hit their primary and secondary Phase 3 endpoints to differentiate torezolid phosphate enough from Zyvox so that a generic Zyvox risk won't be as great. Notwithstanding, it would be nice, assuming Phase 3 trials are successful and FDA approval is received in 2013, if the drug has at least a year on the market before the threat of a generic Zyvox.